Optimization of the Healing Process of the Uterine Scar Tissue After Re-cesarean Section
Launched by MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG · Mar 6, 2016
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
The average number of Cesarean sections in Germany has doubled from 1991 to 2011, making up 32,1% of all deliveries in 2011.
Several studies describe instances in which pregnancies following a previous Cesarean section were accompanied by complications such as life-threatening bleeding, placenta previa, placenta accreta, increta or percreta and dehiscence or uterine rupture.
The risk of those complications increases further with the uterine scar tissue of a second Cesarean section.
Today it is already common practice to resect uterine scars if the scar of a previous Cesarean section beco...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • primary or secondary indication for cesarean section 6 to 9 months prior to the examination date
- Exclusion Criteria:
- • \<18 years old
- • current pregnancy
- • congenital deformity of the uterus
- • former surgery of the uterine myometrium
About Martin Luther Universität Halle Wittenberg
Martin-Luther-Universität Halle-Wittenberg (MLU) is a prestigious research institution located in Halle, Germany, renowned for its commitment to advancing scientific knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, MLU emphasizes rigorous research methodologies and ethical standards, fostering collaboration among interdisciplinary teams to address critical health challenges. The university's extensive network of researchers and clinicians enables the development and execution of high-quality clinical trials aimed at improving patient outcomes and contributing to the global body of medical research. Through its dedication to excellence, MLU plays a pivotal role in translating scientific discoveries into tangible healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halle (Saale), Saxony Anhalt, Germany
Magdeburg, Saxony Anhalt, Germany
Patients applied
Trial Officials
Gregor Seliger, Dr. med.
Principal Investigator
Maternity Clinic/Perinatal Treatment Center, Halle University Hospital, Martin-Luther-Universität Halle-Wittenberg
Michael Tchirikov, Prof.
Study Chair
Maternity Clinic/Perinatal Treatment Center, Halle University Hospital, Martin-Luther-Universität Halle-Wittenberg
Serben-Dan Costa, Prof.
Principal Investigator
Maternity Clinic, Magdeburg University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials